anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Developmental coordination disorder (DCD) is a neurodevelopmental disorder characterised by difficulties in planning and execution of motor coordination activities like dressing, sports and writing. Increasing parents' capacity to manage their children's needs is part of the recommended DCD best practices, as soon as children are suspected to have DCD or early following diagnosis. Parents' capacity could be increased through simple, community-based interventions using a consultative approach. Using the Internet could be an interesting avenue to develop public community-based services and build parents' capacity to manage their child with DCD. The feasibility of recruiting and using the Internet to build parents' capacity is however unknown, since no such study have been conducted.

This randomized feasibility trail will experiment a teleintervention, characterized by a virtual interaction between a health professional and a user by Internet, for children with DCD. The principal study goals are to determine if a randomized control trial would be feasible, particularly with regards to i) recruitment and retention of parents of children having a diagnosis or a suspicion of diagnosis of DCD, and ii) parents' utilization of the teleintervention. The study will also examine quantitatively and qualitatively families' acceptability of- and satisfaction with the teleintervention. As part of the evaluation of acceptability, the impact of the teleintervention on parental competencies will be explored. At the end of the 3-months randomized feasibility trial, the influence of the number of participants on the utilization of the teleintervention will be explored by providing access to the teleintervention to all participants (control and intervention).
Risks of maternal and neonatal complications, even fetal death, increase with prolonged gestation. Recent studies suggest that the risks may start to increase even before 40 weeks of gestation, which challenges the current paradigm of induction after 41 weeks. Preliminary findings seem to suggest that induction before 40 weeks may actually reduce the risk of cesarean delivery. However, induction in women with an unripe cervix has a high risk of failed induction and cesarean delivery. Cervical ripening at hospital prior to induction is also associated with substantial costs and inconvenience to the woman.

Vaginal intercourse in late pregnancy has long been known to women to accelerate the onset of labor. It is recommended by many physicians and nurses to prevent prolonged pregnancy. However, scientific evidence to support this common practice is scarce and inconsistent. We propose a prospective observational study to assess the effects of frequent intercourse on the timing of delivery in term pregnancies.

A total of 510 nulliparous women with low risk pregnancies will be recruited during their antenatal visit after 36 plus 6 and before 39 plus 0 weeks of gestation at the Naval Medical Center San Diego. Subjects who have had infrequent intercourse (less than once per week) during the last four weeks before their visit will be asked to abstain from intercourse for the duration of pregnancy (or use condoms) (we expect to recruit 255 women in this subgroup). Subjects having vaginal intercourse more than once per week during the last four weeks will be asked to maintain or increase their frequency of intercourse up to three times a week (we expect to recruit 255 women for this subgroup). Women will be asked to record physical conditions and vaginal intercourse in a diary until delivery. An ultrasound will assess fetal biometry and cervical length and volume. A pelvic exam will calculate Bishop Score. Obstetric information will be extracted from medical records after birth. Time to delivery and rate of cesarean delivery will be compared between the women without sex and women with frequent sex. The effects of intercourse at term on time to delivery and cesarean delivery may have important clinical implications.
The invention relates to a pharmaceutical composition for treating non-small cell lung cancer, which comprises 50-70 wt% of gefitinib and 30-50 wt% of simvastatin. The non-small cell lung cancer is EGFR T790M Mutant non-small cell lung cancer. The invention also discloses a liposome and a nano-antibody modified liposome, which are obtained by co-incubating the nano-antibody PD-L1 with the liposome. The invention also discloses application of the liposome in preparing a medicament for treating non-small cell lung cancer. The present invention employs a nano-delivery system to co-carry the two drugs. High in tumor microenvironmentThe expression of PD-L1 protein, such as M2 tumor-associated macrophages and tumor vascular endothelial cells highly express PD-L1, so the invention modifies the nano antibody PD-L1 on the surface of the liposome through chemical coupling reaction, and enhances the targeting of the liposome in the tumor microenvironment.
Iron-rich phosphorus (P) sorption materials (PSMs) are often used in P removal structures, a best management practice able to sequester dissolved P from surface runoff, subsurface drainage, and wastewater. The use of bottom-upward flow in these structures is of great interest, but it creates an intrinsic complication: the presence of stagnant water between flow events may cause structures to develop anoxic conditions. It is unknown whether the redox sensitivity of iron (Fe), the predominant element in Fe-rich PSMs, will affect P binding under anoxic conditions. Understanding the potential impact of intermittent anoxic conditions on the solubility of previously adsorbed P is imperative for determining the feasibility of the bottom-up flow design. The objective of this research was to investigate the (1) development of anoxic conditions in the presence of Fe-rich PSM and tile drainage, (2) Fe-bound P mobilization and solubility, and (3) changes in P sorption capacity of Fe-rich PSMs after oxic conditions are restored. Three Fe-rich PSMs were tested in batch incubation studies: acid mine drainage residual, Fe-coated alumina, and steel metal shavings. Non-treated and P-treated PSM samples were incubated in biogeochemical reactors for as long as necessary to reach Eh = -200 mV. After incubation, dissolved P concentrations in P-treated samples and non-treated samples were similarly low, indicating stability of P retention of PSMs under anoxic conditions. The P removal ability of non-treated PSMs before and after undergoing incubation was not significantly altered, as determined in flow-through experiments. Potentially harmful trace metals were not detected in the incubated solutions. Our research shows that the development of anoxic conditions does not significantly impact PSMs Fe-bound P dissolution, and the P removal ability of PSMs persists after oxic conditions are reestablished.
The present invention provides a composition which includes one or more organic suncreens and colloidal silicon dioxide. Preferably, the colloidal silicon dioxide is prewetted with a liquid, such as liquid silicone. In another embodiment, the present invention provides a composition for topical application to the lips or oval cavity. The composition includes a topically applicable anhydrous base; a malflavored organic sunscreen; and a malflavored organic sunscreen taste-masking effective amount of colloidal silicon dioxide. In yet another embodiment, a method of preparing the composition of the present invention is provided. The method includes the steps of (a) mixing silicon dioxide and a liquid, such as silicone; (b) adding the mixture of step (a) to a melted anhydrous base material; (c) adding an organic sunscreen to the mixture of step (b); and (d) cooling the mixture of step (c).
This is a single-center, open labeled, single-arm study in patients with previously untreated unresectable biliary tract cancer. This trial will follow a Simon's two-stage optimal design. For the first stage, 9 patients will be accrued. If none of the 9 patients have controlled disease with mFOLFOX6 in combination with bevacizumab, the combination will be rejected and the trial stopped. However, if at least 1 patient of the 9 (11%) respond to treatment in the first stage, then an additional 15 patients will be entered into the second stage, for a total of 24 patients in the phase II study. If 3 (13%) or more patients respond to therapy, then the combination will be considered for further investigation.
Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in "error reduction" mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period.
In an oral (gavage) mouse carcinogenicity study, doses of 0.1, 0.3, and 1 mg/kg/day fluticasone propionate were administered to mice for 18 months. Fluticasone propionate demonstrated no tumorigenic potential at oral doses up to 1 mg/kg/day in this study.

In a dermal mouse carcinogenicity study, 0.05% fluticasone propionate ointment (40 μl) was topically administered for 1, 3 or 7 days/week for 80 weeks. Fluticasone propionate demonstrated no tumorigenic potential at dermal doses up to 6.7 μg/kg/day in this study.

Fluticasone propionate was not mutagenic or clastogenic in five in vitro genotoxicity tests (Ames assay, E. coli fluctuation test, S. cerevisiae gene conversion test, Chinese hamster ovary cell chromosome aberration assay and human lymphocyte chromosome aberration assay) and one in vivo genotoxicity test (mouse micronucleus assay).

In a fertility study, male and female rats received subcutaneous doses of fluticasone propionate at doses up to 50 μg/kg/day. No impairment of fertility or mating performance was observed.
The condition of the patients was evaluated, and the total length of both lower limbs, anteroposterior position of knee and Mri of knee were included. The preoperative dose of tranexamic acid was calculated according to body weight of 20 mg / kg, 100 ml of tranexamic acid sodium chloride solution was dripped 30 minutes before operation, and after incision closure, 30 ml of normal saline solution containing 2 g of tranexamic acid was injected through drainage tube or subcutaneously. Postoperative intravenous drip of 100 ML sodium chloride solution containing 20 mg / kg tranexamic acid. Arthroscopy was first used to further confirm the cartilage defect, and a new type of lower limb alignment meter and a customized precise osteotomy template were used to perform the osteotomy according to the preoperative plan. One group was not placed drainage tube, the other group was placed drainage tube. Visual analogue pain score (Vas) and American Special Surgical Hospital (HSS) knee function score were recorded 3 month after surgery. Throughout the trial, the investigators will carefully observe and manage your complications and the outcome of your surgery.
The invention belongs to the technical field of porous covalent organic framework materials and medical biology, and discloses a fluorine functional group covalent organic framework material, a preparation method and application thereof. The invention provides a chemical structural formula of a TP-DFPA-COF material. Provides a preparation method of TP-DFPA-COF material loaded with various anti-cancer drugs and drugs for treating hyperuricemia. Also provides the application of the TP-DFPA-COF material in the aspect of in-vitro drug slow release performance after loading various anti-cancer drugs and drugs for treating hyperuricemia. The fluorescent COF material with the fluorine-containing group has simple synthesis steps and high yield, and can be amplified to the specification above gram level. The COF material has good dispersibility and stability in various organic solvents and water, and is acid-base resistant and high-temperature resistant. The fluorine radical in the material and the drug molecule form hydrogen bond acting force, so that the chemical bond load with high bond energy is avoided, and a high load rate can be achieved.
In PREVENT, 825 patients with angiographically documented coronary artery disease were randomized to NORVASC

(5–10 mg once daily) or placebo and followed for 3 years. Although the study did not show significance on the primary objective of change in coronary luminal diameter as assessed by quantitative coronary angiography, the data suggested a favorable outcome with respect to fewer hospitalizations for angina and revascularization procedures in patients with CAD.

CAMELOT enrolled 1318 patients with CAD recently documented by angiography, without left main coronary disease and without heart failure or an ejection fraction <40%. Patients (76% males, 89% Caucasian, 93% enrolled at US sites, 89% with a history of angina, 52% without PCI, 4% with PCI and no stent, and 44% with a stent) were randomized to double-blind treatment with either NORVASC (5–10 mg once daily) or placebo in addition to standard care that included aspirin (89%), statins (83%), beta-blockers (74%), nitroglycerin (50%), anti-coagulants (40%), and diuretics (32%), but excluded other calcium channel blockers. The mean duration of follow-up was 19 months. The primary endpoint was the time to first occurrence of one of the following events: hospitalization for angina pectoris, coronary revascularization, myocardial infarction, cardiovascular death, resuscitated cardiac arrest, hospitalization for heart failure, stroke/TIA, or peripheral vascular disease. A total of 110 (16.6%) and 151 (23.1%) first events occurred in the NORVASC and placebo groups, respectively, for a hazard ratio of 0.691 (95% CI: 0.540–0.884, p = 0.003). The primary endpoint is summarized in Figure 1 below. The outcome of this study was largely derived from the prevention of hospitalizations for angina and the prevention of revascularization procedures (see Table 1). Effects in various subgroups are shown in Figure 2.

In an angiographic substudy (n=274) conducted within CAMELOT, there was no significant difference between amlodipine and placebo on the change of atheroma volume in the coronary artery as assessed by intravascular ultrasound.

Figure 1 - Kaplan-Meier Analysis of Composite Clinical Outcomes for NORVASC versus Placebo 

Figure 2 – Effects on Primary Endpoint of NORVASC versus Placebo across Sub-Groups 

Table 1 below summarizes the significant composite endpoint and clinical outcomes from the composites of the primary endpoint. The other components of the primary endpoint including cardiovascular death, resuscitated cardiac arrest, myocardial infarction, hospitalization for heart failure, stroke/TIA, or peripheral vascular disease did not demonstrate a significant difference between NORVASC and placebo.
Annual lung cancer screening using low-dose computed tomography (LDCT) is associated with decreased lung cancer mortality but also with harms. As such, it is recommended, and required for reimbursement, that patients complete an shared decision-making visit (SDM) prior to screening to discuss potential risks and benefits in the context of patient values. Despite guidelines recommending screening and national insurance coverage of LDCT, uptake of SDM visits and subsequent LDCT is remarkably low. We aim to address these gaps by comparing the effectiveness of synchronous and asynchronous telehealth strategies on SDM visits and subsequent LDCT in a pragmatic trial using a Sequential Multiple Assignment Randomized Trial (SMART) design. The specific first stage strategies to be tested are: a) Active Choice Outreach (invitation to schedule a telehealth or in-person SDM visit) vs b) Telehealth Only Outreach (invitation to schedule a telehealth SDM visit). The specific second stage strategies (delivered only if participants do not respond to first stage interventions) are a) text message reminders encouraging SDM visit completion (low-touch) alone or b) in combination with phone-based digital care coordination (high-touch). We will also assess non-inferiority of strategies by race and sex to assess equity of effectiveness.
The invention discloses sophora tonkinensis endophytic fungus GRPH-0. The sophora tonkinensis endophytic fungus GRPH-0 has the type name of Myrothecium sp. GRPH-0, an ITS sequence of the Myrothecium sp. GRPH-0 is as shown in SEQ ID NO. 1, and the Myrothecium sp. GRPH-0 is collected by the General Microorganisms Center of China Committee for Culture Collection of Microorganisms, which is located at Institute of Microbiology, Chinese Academy of Sciences, 3#, 1# Courtyard, Beichen West Road, Chaoyang District, Beijing, on September 29, 2015 and has the collection number of CGMCC No. 11391. According to the sophora tonkinensis endophytic fungus GRPH-0, the Myrothecium sp. GRPH-0 has a very remarkable inhibiting action on the Candida albicans; a method for preparing metabolites of the endophytic fungus Myrothecium sp. GRPH-0 is easy and feasible and is low in cost.
INTRODUCTION: Patients with chronic obstructive pulmonary disease (COPD) are frequently colonized and infected by respiratory pathogens. Identifying these infectious etiologies is critical for understanding the microbial dynamics of COPD and for the appropriate use of antimicrobials during exacerbations.
AREAS COVERED: Traditional methods, such as bacterial and viral cultures, have been standard in diagnosing respiratory infections. However, these methods have significant limitations, including lack of sensitivity and prolonged turnaround time. Modern molecular approaches offer rapid, sensitive, and specific detection, though they also come with their own challenges. This review explores and evaluates the clinical utility of the latest advancements in detecting bacterial and viral respiratory infections in COPD, encompassing molecular techniques, biomarkers, and emerging technologies.
EXPERT OPINION: In the evolving landscape of COPD management, integrating molecular diagnostics and emerging technologies holds great promise. The enhanced sensitivity of molecular techniques has significantly advanced our understanding of the role of microbes in COPD. However, many of these technologies have primarily been developed for pneumonia diagnosis or research applications, and their clinical utility in managing COPD requires further evaluation.
Solid particles are coated by suspending the particles as a fluidized bed in a gas stream of non-uniform upward velocity such that in one portion of the bed in which the gas stream moves with a relatively high velocity, the particles move upwards substantially out of contact with each other and in that part in which the gas stream moves with a relatively lower velocity, the particles move downwards in substantially weightless contact with each other, the coating materials being introduced into the gas stream at the lower end of the upwardly flowing part of the bed. For producing nonuniformity of gas velocity grids or screens of non-uniform aperture size or in which the "mesh" only covers a portion of the conduit may be placed in the gas conduit.  These may be replaced or used in combination with movable "damper" plates.  The coating compositions used may be liquids or finely-divided solids, e.g. aqueous sugar solutions and compositions comprising film-forming substances, e.g. polyvinyl alcohol, cellulose acetate phthalate and zein, natural and synthetic resins, e.g. shellac, alkyl and silicone resins, waxes and waxy materials, e.g. polyvinyl pyrrolidone, glyceryl monostearate and glyceryl monostearate, plasticizing agents, colouring agents and bulking substances, e.g. starch, talc or magnesium carbonate.ALSO:Solid particles, e.g. medicinal tablets, are coated by suspending the particles in an upwardly flowing gas stream containing coating material and causing circulation of the particles in the fluidized bed by directing the gas stream through one portion of the bed at a higher velocity than through another portion, the gas velocity being such that the particles flow upwards in the high velocity region and flow downwardly in weightless contact in the region of lower velocity, the particles p  in the upward flowing region being substantially out of contact with each other.  The coating materials are directed into the lower end of the upwardly flowing gas stream and for causing the variable gas flow velocity, there may be used grids or screens in which the size of the openings is not uniform or in which the mesh only partially covers the gas conduit in which they are placed beneath the fluidized bed and which may be replaced or used in combination with movable "damper" plates.
Systems and methods for compounding pharmaceuticals, for example for intravenous delivery. The devices include an infrared camera and an infrared light source, and can backlight and photograph items such as syringes in infrared light for enhanced clarity. A visible light camera may also be provided, for example a color digital camera, for documenting other parts of the compounding process. The device may have other sensors, for example a bar code scanner and a weight sensor, for collecting other data about the compounding process. In one example implementation, the device is a compounding assistance device that leads a user of the device through a compounding task using instructions shown on a display. In other implementations, the device may be robotic.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia treatable with antiarrhythmic drugs; however, patient responses remain highly variable. Human induced pluripotent stem cell-derived atrial cardiomyocytes (iPSC-aCMs) are useful for discovering precision therapeutics, but current platforms yield phenotypically immature cells and are not easily scalable for high-throughput screening. Here, primary adult atrial, but not ventricular, fibroblasts induced greater functional iPSC-aCM maturation, partly through connexin-40 and ephrin-B1 signaling. We developed a protein patterning process within multiwell plates to engineer patterned iPSC-aCM and atrial fibroblast coculture (PC) that significantly enhanced iPSC-aCM structural, electrical, contractile, and metabolic maturation for 6+ weeks compared to conventional mono-/coculture. PC displayed greater sensitivity for detecting drug efficacy than monoculture and enabled the modeling and pharmacological or gene editing treatment of an AF-like electrophysiological phenotype due to a mutated sodium channel. Overall, PC is useful for elucidating cell signaling in the atria, drug screening, and modeling AF.
To investigate the symptoms of SARS-CoV-2 infection, their dynamics and their discriminatory power for the disease using longitudinally, prospectively collected information reported at the time of their occurrence. We have analysed data from a large phase 3 clinical UK COVID-19 vaccine trial. The alpha variant was the predominant strain. Participants were assessed for SARS-CoV-2 infection via nasal/throat PCR at recruitment, vaccination appointments, and when symptomatic. Statistical techniques were implemented to infer estimates representative of the UK population, accounting for multiple symptomatic episodes associated with one individual. An optimal diagnostic model for SARS-CoV-2 infection was derived. The 4-month prevalence of SARS-CoV-2 was 2.1%; increasing to 19.4% (16.0%-22.7%) in participants reporting loss of appetite and 31.9% (27.1%-36.8%) in those with anosmia/ageusia. The model identified anosmia and/or ageusia, fever, congestion, and cough to be significantly associated with SARS-CoV-2 infection. Symptoms' dynamics were vastly different in the two groups; after a slow start peaking later and lasting longer in PCR+ participants, whilst exhibiting a consistent decline in PCR- participants, with, on average, fewer than 3 days of symptoms reported. Anosmia/ageusia peaked late in confirmed SARS-CoV-2 infection (day 12), indicating a low discrimination power for early disease diagnosis.